LAS VEGAS, Oct. 14 /PRNewswire/ -- Nucleix, Ltd., an emerging life science company specializing in forensic DNA analysis, announced that company researchers today presented its DNA authentication technology, a novel assay to distinguish between in-vivo (real) and in-vitro (fake) DNA, at the 20th International Symposium on Human Identification in Las Vegas, Nevada.
Earlier this year, Nucleix scientific co-founders Adam Wasserstrom, Ph.D., and Dan Frumkin, Ph.D., demonstrated that DNA evidence found at crime scenes can easily be falsified using basic equipment, know-how and access to DNA or a DNA database (1). Recognizing the need to safeguard the accuracy and credibility of DNA evidence in the field of forensics, the scientists developed a novel "DNA authentication" assay for combating this form of biological identity theft. Their study was published in the forensic industry's leading peer-reviewed scientific journal, "Forensic Science International: Genetics."
The Nucleix authentication assay is based on the fact that real DNA differs from fake DNA in biochemical properties, such as the methylation pattern. Specifically, in vivo-generated DNA contains genomic loci that are completely and consistently methylated and other loci that are unmethylated, differing from in vitro-synthesized DNA, which is completely unmethylated. Nucleix's novel proprietary assay can identify and differentiate between real and all potential types of fake DNA through methylation analysis of a set of genomic loci. In this symposium, Dr. Frumkin presented further developments of the company's DNA authentication technology. The Nucleix assay is comprised of a biochemical procedure followed by automatic signal analysis by a software application specifically designed for DNA authentication.
Details unveiled by Nucleix today demonstrate the ability to seamlessly integrate the company's DNA authenticat
|SOURCE Nucleix, Ltd.|
Copyright©2009 PR Newswire.
All rights reserved